Genmab A/S (NASDAQ:GMAB) Releases Quarterly Earnings Results, Misses Estimates By $0.41 EPS

Genmab A/S (NASDAQ:GMAB) released its quarterly earnings data on Tuesday. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41), Zacks reports. The firm had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.06 billion. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%.

Here are the key takeaways from Genmab A/S’s conference call:

• Genmab reported 2025 revenue of $3.7 billion (up 19%) and expanded operating profit to $1.26 billion, while guiding 2026 revenue growth around the midpoint of 14% and targeting gross leverage below 3x by end-2027.
• Commercial momentum accelerated: proprietary medicines totaled $632 million (up 54%), with Epkinly at $468 million (+67%) and Tivdak $164 million (+26%), and Epkinly now approved in >65 countries as Genmab expands direct commercialization in Europe, Japan and the U.S.
• The Merus acquisition added petosemtamab, giving Genmab three late‑stage programs (Epkinly, Rina‑S, petosemtamab) with five breakthrough designations that management says have multi‑billion dollar potential.
• The EPCORE DLBCL‑1 Phase III of Epkinly showed a PFS benefit but missed statistical significance for overall survival, and Genmab will discuss next steps with regulators while asserting other Phase III trials remain viable as confirmatory evidence.
• 2026 is framed as a catalyst year with up to six potentially registrational readouts (including frontline and second‑line Epkinly combos, a Rina‑S readout in PROC, and one or both petosemtamab Phase IIIs), which could set the stage for multiple 2027 launches.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB traded down $0.74 during trading hours on Wednesday, hitting $29.27. 1,196,801 shares of the company’s stock traded hands, compared to its average volume of 1,777,532. The company’s fifty day simple moving average is $32.30 and its two-hundred day simple moving average is $29.88. The company has a market cap of $18.80 billion, a price-to-earnings ratio of 12.47, a price-to-earnings-growth ratio of 17.63 and a beta of 0.90. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $35.43.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on GMAB shares. HC Wainwright boosted their price objective on Genmab A/S from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday. Morgan Stanley assumed coverage on shares of Genmab A/S in a report on Monday. They issued an “equal weight” rating and a $34.00 price objective for the company. Truist Financial reissued a “buy” rating and set a $48.00 target price (down previously from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Wall Street Zen lowered shares of Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Finally, Jefferies Financial Group initiated coverage on shares of Genmab A/S in a research note on Tuesday. They set a “buy” rating and a $41.50 price objective on the stock. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.30.

Genmab A/S News Summary

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Company announced a targeted share buy‑back to repurchase up to 342,130 shares (max ~725 million DKK) to satisfy Restricted Stock Unit obligations; program completes by March 31, 2026 — reduces share count and supports EPS. Article Title
• Positive Sentiment: Analyst momentum: HC Wainwright raised its target to $40 (buy) and Jefferies initiated coverage with a $41.50 buy target; Morgan Stanley also began coverage and broker consensus is a “Moderate Buy” — these lifts can attract demand and support higher valuations. Article Title Article Title Article Title
• Neutral Sentiment: Reported Q4 operationals showed strong revenue (~$1.06B) and company commentary highlighted revenue growth and strategic expansion; mixed readthrough on profitability as some sources differ on exact EPS beats. Investors will focus on underlying revenue growth and guidance cadence. Article Title Article Title
• Neutral Sentiment: Genmab published its 2025 Annual Report and filed Form 20‑F with the SEC — provides updated financials, strategy commentary and the company’s outlook for 2026; useful for longer‑term modeling but not an immediate catalyst. Article Title Article Title
• Neutral Sentiment: Notice of Annual General Meeting set for March 19, 2026 — routine corporate governance item; potential minor share‑holder/board impacts depending on votes. Article Title
• Neutral Sentiment: Reported short‑interest data in the feed appears inconsistent/unreliable (NaN/zero entries) — no clear short‑pressure signal from this update. (Data quality flag.)
• Negative Sentiment: An earnings call transcript published by a third party shows a reported EPS figure below expectations (one transcript notes $0.4035 vs ~$0.46 est.), which could explain some intra‑day selling or caution; note there are conflicting EPS figures across sources, so market reaction may reflect uncertainty. Article Title

Institutional Trading of Genmab A/S

A number of hedge funds have recently bought and sold shares of GMAB. Orbis Allan Gray Ltd grew its holdings in shares of Genmab A/S by 30.2% during the 4th quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock valued at $444,089,000 after acquiring an additional 3,340,456 shares in the last quarter. Paradigm Biocapital Advisors LP raised its holdings in shares of Genmab A/S by 84.4% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,039,834 shares of the company’s stock worth $216,827,000 after acquiring an additional 3,222,983 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in Genmab A/S by 5.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,643,139 shares of the company’s stock valued at $111,735,000 after purchasing an additional 188,761 shares during the last quarter. Renaissance Technologies LLC boosted its position in Genmab A/S by 23.8% during the fourth quarter. Renaissance Technologies LLC now owns 3,492,850 shares of the company’s stock valued at $107,580,000 after purchasing an additional 671,307 shares during the last quarter. Finally, Morgan Stanley grew its stake in Genmab A/S by 9.5% in the fourth quarter. Morgan Stanley now owns 1,834,439 shares of the company’s stock valued at $56,501,000 after purchasing an additional 159,865 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.